We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
An assistant professor at the state University at Albany's Gen*NY*Sis Center
for Excellence in Cancer Genomics has been awarded a $1.43 million research
grant from the National Institutes of Health.
Cleveland BioLabs (CBL), a Cleveland Clinic spin-off developing new therapies
to reduce the negative effects of cancer treatment and enhance the ability of
people to withstand radiation exposure, has received a $5.9 million investment
from a group of institutional and private investors led by Sunrise Equity Partners,
L.P. of New York.
Dainippon Pharmaceutical and Zoegene jointly announced
on March 23 that they have entered into a joint research agreement in the fields
of diabetes and obesity.
The FDA has issued a warning letter to Canadian drugmaker Germiphene after an
inspection of the company's Brantford, Ontario, plant revealed significant deviations
from current good manufacturing practices (cGMPs).
Before safety concerns over Cox-2 inhibitors and antidepressant use in children
made front-page headlines, the pharmaceutical industry had to deal with revelations
that widely used hormone replacement therapies (HRTs) posed significant health
risks -- a finding that is now being questioned by an industry analyst.
Tremendous advances in the biopharmaceutical
sciences, including in the field of genomics, have given pharmaceutical firms
vast amounts of new information on which to develop drugs -- a key development
that will fundamentally change the way drugmakers operate, industry experts
say.
Schering AG and Novartis have pushed back the development timetable for one
of their most important pipeline candidates -- experimental colon-cancer drug
PTK/ZK -- after it failed to stop the growth of tumors in a Phase III study,
the companies said.
Iowa residents will have to show ID and sign their names when buying cold medicines
containing pseudoephedrine under an anti-methamphetamine law approved by state
lawmakers this week.
Lion Bioscience AG said shareholder Ian Humphrey-Smith has informed its extraordinary
general meeting of a possible takeover offer for the company by a group of investors.
Two big Japanese drugmakers are merging -- and New Jersey is the loser. Next
month, Yamanouchi Pharmaceuticals and Fujisawa Pharmaceuticals will form Astellas
Pharma, and locate their U.S. headquarters in Fujisawa offices in Deerfield,
Ill.